The successful closing of the public offering and the full exercise of the underwriter's option suggest strong investor demand and confidence in atai Life Sciences. This capital raise strengthens the company's financial position, potentially supporting its clinical-stage biopharmaceutical initiatives. The positive market reception is likely to have a favorable short-term impact on the stock price.